Alzheimer's Disease Market

Feb 12, 2025

Alzheimer’s disease is a devastating neurodegenerative disorder that affects millions worldwide, progressively impairing memory, cognitive function, and independence. Despite extensive research, current Alzheimer’s disease drugs provide only limited relief, and there remains no cure. With the number of cases projec...

Feb 12, 2025

Alzheimer’s disease has become one of the most pressing global health challenges, with its prevalence rising dramatically over the past few years. As the aging population grows, so does the burden of this neurodegenerative disorder, placing immense strain on healthcare systems worldwide. The Alzheimer's drug market...

Feb 12, 2025

Alzheimer’s disease currently affects an estimated 50 million people worldwide. This number is projected to rise to 75 million by 2030 and a staggering 131.5 million by 2050, according to Alzheimer's Disease International, spanning all age groups globally. While the exact cause of Alzheimer’s disease remains elusiv...

Feb 12, 2025

Alzheimer's disease continues to pose a significant challenge to global healthcare systems, with the 7MM reporting approximately 16 million diagnosed prevalent cases in 2023. This rising AD prevalence highlights an urgent need for innovative treatments to mitigate the growing disease burden on both patients and car...

Feb 12, 2025

Alzheimer’s disease is the most common type of dementia, accounting for more than 60% of all cases, and is characterized by a gradual decline in cognitive and functional abilities. It represents a global health crisis that is increasing with the increasing geriatric population. It represents a global health crisis ...

Jul 08, 2024

The world of Alzheimer’s disease treatment witnessed a groundbreaking moment recently as the FDA approved Eli Lilly’s donanemab, marketed as KINSUNLA. This new drug brings hope to millions of patients and their families struggling with this debilitating disease. Let us delve into the fascinating journey of donanema...

May 21, 2024

IMDELLTRA Receives FDA Approval as the First T-Cell Engager Therapy for Advanced Small Cell Lung Cancer Amgen has reported that the FDA has approved IMDELLTRA™ (tarlatamab-dlle) for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following pl...

May 14, 2024

Takeda and AC Immune Ink Exclusive Deal for Active Immunotherapy in Alzheimer’s, Focusing on Amyloid Beta Takeda and AC Immune SA have unveiled an exclusive global option and licensing pact concerning AC Immune’s active immunotherapies directed at harmful variants of amyloid beta (Abeta), notably ACI-24.060, int...

Jun 24, 2020

Alzheimer's is a progressive brain disorder that results in the degeneration of brain cells. It affects the thinking, reasoning, memory, and problem-solving skills of the person. Apart from cognitive function, it also influences mood, personality, behavior, and social skills. In the advanced stages, the patients ar...

Jun 17, 2020

50 million people globally have dementia, and out of all the dementia cases, Alzheimer’s Disease accounts for about 60–70% of cases, says the WHO. Alzheimer's Disease is a neurodegenerative disease, a common cause of dementia that affects behavior, memory, and thinking abilities of an individual. Mostly the symptom...